A hat-tip to Kowa Pharmaceuticals America Inc. on its recent agreement with Allergan plc. to co-promote Allergan’s Bystolic® beta blocker in the United States.
Kowa’s nationwide sales force will co-promote Bystolic to cardiologists and primary care providers, with the company’s cholesterol-lowering drug LIVALO® (pitavastatin) tablets.
“Kowa has a long history of successfully co-promoting products within the cardiometabolic space, and this new partnership with Allergan aligns closely with our focus and expertise in the area of cardiometabolic diseases,” said Ben Stakely, Chairman and CEO of Kowa Pharmaceuticals.
He added: “We remain committed to patients and healthcare professionals, and to providing therapies that help address serious and chronic conditions including high cholesterol and high blood pressure. Adding Bystolic to our product portfolio expands our offering and will enhance our ability to support patients suffering from these diseases, which represent a significant public health issue.”Kowa Pharmaceuticals is a valued LSPediA partner. In December, Kowa announced an expansion of its existing relationship with LSPediA. LSPediA will provided Verification Router Services (VRS) to Kowa including Saleable Returns Verification, Non-saleable Returns Decommission, Lookup Directory Synchronization, and VRS Dashboard.
Through its partnership with LSPediA, Kowa has responded to thousands of VRS requests from the leading wholesalers in the US. LSPediA’s VRS allows companies to verify serialized Rx products for authenticity, decommission unsaleable returns, and initiate notification for recalls or counterfeit.
Kowa and LSPediA first teamed up 2015 on DSCSA compliance, and soon added LSPediA’s EPCIS system, WarehouseEdge, and CMO management consulting.
KowaPharmaceuticals America, headquartered in Montgomery, Alabama, focuses primarily in cardiometabolic diseases. Learn more here.
Have news to announce about your company? LSPediA is proud to give a shout-out to important events and accomplishments by all our business partners. Send your news to Communications Director Brian O’Connor.